In the quest to find therapies for multi-drug resistant HIV, researchers have zeroed in on raltegravir. The latest data indicates this potent agent provides the highest reported virologic suppression rate among multi-drug resistant patients. Is raltegravir proving more effective than antiretrovirals? Does it carry any prominent side effects? Dr. Roy Steigbigel, professor of medicine and pathology, molecular genetics and microbiology, and pharmacological sciences, and founding director of the Comprehensive AIDS Center at the State University of New York at Stony Brook, details his New England Journal of Medicine research on raltegravir therapy for multi-drug resistant HIV with host Dr. Mark Nolan Hill.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Raltegravir Therapy for Multi-Drug Resistant HIV
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
In the quest to find therapies for multi-drug resistant HIV, researchers have zeroed in on raltegravir. The latest data indicates this potent agent provides the highest reported virologic suppression rate among multi-drug resistant patients. Is raltegravir proving more effective than antiretrovirals? Does it carry any prominent side effects? Dr. Roy Steigbigel, professor of medicine and pathology, molecular genetics and microbiology, and pharmacological sciences, and founding director of the Comprehensive AIDS Center at the State University of New York at Stony Brook, details his New England Journal of Medicine research on raltegravir therapy for multi-drug resistant HIV with host Dr. Mark Nolan Hill.
Presenters
Facebook Comments